SCISSOR N3
In vitro testing of Subcutaneous (SC) monoclonal antibodies (mAbs)
Ensuring absorption and bioavailability of your subcutaneous (SC) mAb therapy is critical for drug effectiveness. For a long time, scientists’ primary method for testing formulations was using animals.
In 2025, the FDA has released new guidance on testing subcutaneous (SC) monoclonal antibodies (mAbs) and lays out support for in vitro New Approach Methodologies (NAMs) to reduce animal testing for SC monoclonal antibody (mAb) drugs.
This shift is historic, cutting down on ethically challenging, time-consuming, and costly animal studies, while accelerating access to life-saving medicines.
At Pion, we’ve been pushing this approach since our inception and we’re thrilled the regulatory community will be joining us on this journey.
We ARE the SubCutaneous Injection Site SimulatOR – SCISSOR N3™!
Pion developed and validated SCISSOR N3 using mAbs 10 years ago, specifically to simulate SC drug behavior in vitro, enabling informed prediction and comparison of drug performance in vitro, helping reduce animal testing today, not years from now.
The FDA’s shift is a leap forward—and we’re already there.
Want to Learn More?
Listen to Pion’s Development Scientist, Conor Gomes summarize a recent publication by AstraZeneca in the Journal of Controlled Release where they used SCISSOR to investigate in vitro – in vivo correlations: ‘Predicting human subcutaneous bioavailability of monoclonal antibodies using an integrated in-vitro/in silico approach’
Lorem Ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit.